LEX Diagnostics
LEX Diagnostics is a privately held molecular diagnostics company focused on developing ultra-fast, high-sensitivity PCR point-of-care testing systems. Their mission is to redefine point-of-care diagnostics by delivering clinical insights within minutes, supporting healthcare providers with lab-quality results in a user-friendly system. They aim to improve patient care through rapid, accurate, and accessible molecular testing, with a focus on infectious diseases such as COVID-19, Influenza, Strep A, and RSV.
Industries
Nr. of Employees
small (1-50)
LEX Diagnostics
Melbourn Science Park, Melbourn, SG8 6EE, UK
Patents
Products
Ultra-fast point-of-care PCR system (instrument and cartridge assays)
An integrated point-of-care molecular diagnostic platform comprising a compact instrument and single-use cartridges that performs multiplex PCR directly from swab samples with automated, no-liquid-handling workflow and time-to-result reported in approximately 6–10 minutes.
Ultra-fast point-of-care PCR system (instrument and cartridge assays)
An integrated point-of-care molecular diagnostic platform comprising a compact instrument and single-use cartridges that performs multiplex PCR directly from swab samples with automated, no-liquid-handling workflow and time-to-result reported in approximately 6–10 minutes.
Expertise Areas
- Point-of-care molecular diagnostics
- Assay development for respiratory syndromic testing
- Reagent formulation and lyophilisation
- Consumables manufacturing and scale-up
Key Technologies
- Rapid thermal cycling for PCR
- Multiplex PCR assays
- Cartridge-based sample-to-answer systems
- Swab-to-result automated workflows
News & Updates
LEX Diagnostics has submitted dual applications to the FDA seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform for respiratory pathogens, with results in under ten minutes.
LEX Diagnostics announced the appointment of Dr Heather Danks as its CTO, focusing on developing the LEX platform and advancing its rapid PCR technology.
Scott O’Brien, a senior business leader with over 25 years of experience in life sciences and diagnostics, has been appointed to the LEX board.
Ed Farrell, with over 25 years of experience in life sciences, was appointed as CEO to lead the company’s efforts in bringing rapid molecular diagnostics to market.
The core innovation making 5-minute sample-to-answer possible is secured.
LEX Diagnostics has submitted dual applications to the FDA seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform for respiratory pathogens, with results in under ten minutes.
LEX Diagnostics announced the appointment of Dr Heather Danks as its CTO, focusing on developing the LEX platform and advancing its rapid PCR technology.
Scott O’Brien, a senior business leader with over 25 years of experience in life sciences and diagnostics, has been appointed to the LEX board.
Ed Farrell, with over 25 years of experience in life sciences, was appointed as CEO to lead the company’s efforts in bringing rapid molecular diagnostics to market.
The core innovation making 5-minute sample-to-answer possible is secured.